What Is PIGD? Inherited GPI Anchor Deficiency

PIGD, short for phosphatidylinositol glycan anchor biosynthesis class D, is one of more than twenty genes involved in building GPI anchors, the molecular tethers that attach hundreds of proteins to the outer surface of human cells. When any gene in this pathway is disrupted by inherited mutations, the result is an inherited glycosylphosphatidylinositol deficiency disorder, usually called IGD. These rare conditions typically cause seizures, intellectual disability, and distinctive facial features in early childhood, though the severity varies considerably depending on which gene is affected.

What GPI Anchors Actually Do

Cells rely on a lipid-and-sugar structure called a GPI anchor to hold certain proteins in place on their outer membrane. Without it, those proteins either never reach the cell surface or get released into the bloodstream instead of staying put. The list of GPI-anchored proteins is long and functionally diverse: enzymes, immune regulators, signaling molecules, and complement-defense proteins all depend on this system. When the assembly line that builds GPI anchors stalls partway through, the downstream effects ripple across multiple organ systems.

The pathway that constructs GPI anchors involves a chain of enzymatic steps carried out inside the endoplasmic reticulum, a compartment within every cell. The very first step transfers a sugar onto a lipid backbone. That reaction requires a protein complex made up of several subunits encoded by different PIG genes. Research on this first enzyme complex showed that four mammalian gene products, including PIG-A, PIG-H, and PIG-C, assemble together in the ER membrane and carry out the initial sugar-transfer reaction in laboratory conditions.¹ Additional subunits, including a small protein called PIG-P, were later identified. A yeast study confirmed that PIG-P’s counterpart in that organism is essential for the same enzyme to function, underscoring how ancient and conserved this machinery is across species separated by over a billion years of evolution.²

PIGD itself contributes to a later step in this biosynthetic chain. Each PIG gene encodes a component responsible for a particular reaction, whether that is adding a sugar, transferring a lipid, or remodeling the anchor’s fatty acid tail. A mutation in any one of these genes can slow or halt production of finished GPI anchors, which is why mutations across more than a dozen different PIG genes all lead to overlapping but not identical clinical syndromes.

How Inherited GPI Deficiency Presents

Children with IGD almost always come to medical attention early. Seizures are the most common presenting feature, often beginning in the first months of life and proving difficult to control with standard antiepileptic drugs. Developmental delay or intellectual disability is present in nearly every case, ranging from moderate to profound. Reduced muscle tone, called hypotonia, is also typical, and many affected children have characteristic facial features such as a wide nasal bridge, thin upper lip, or tented upper lip.

Beyond the nervous system, IGD can involve the skeleton, heart, kidneys, and gastrointestinal tract. Some children have structural brain abnormalities visible on MRI. Others develop scoliosis or have abnormalities of the skull bones. The specific mix of features depends heavily on which PIG gene carries the mutation, a point that matters for both prognosis and genetic counseling.

Why Different PIG Genes Produce Different Severity

A large study examining the clinical and genetic spectrum of IGD disorders used clustering analysis to group patients by their features and outcomes. The results revealed meaningful patterns. PIGG mutations, for instance, consistently produced a milder form of IGD compared with other gene groups, standing out as an outlier in both how patients looked clinically and how they fared over time.³ PIGN mutations also tended toward a milder phenotype, with fewer distinguishing features compared to the broader cohort.

At the more severe end, PIGA and PIGT mutations clustered together phenotypically. Both groups showed high rates of seizures, hypotonia, weakness, skull-shape abnormalities, and abnormal brain MRI findings. But even within that shared severity, the two genes had distinguishing signatures. PIGT mutations were associated with prominent gastrointestinal problems, motor symptoms, and lower-than-expected alkaline phosphatase, while PIGA mutations were more strongly linked to cardiac involvement, kidney problems, scoliosis, and elevated alkaline phosphatase.⁴ These differences matter because they can guide clinicians toward the right gene when interpreting a child’s symptoms before genetic testing results come back.

Elevated Alkaline Phosphatase as a Diagnostic Clue

One of the most distinctive laboratory findings in certain IGD subtypes is an abnormally high level of serum alkaline phosphatase, or ALP. ALP is an enzyme that normally sits on the cell surface, tethered by a GPI anchor. When the anchor is missing or malformed, ALP gets released into the bloodstream instead of staying on the membrane. The result is a blood test showing ALP levels far above the normal range.

This connection was first worked out in detail for mutations in PIGV, where researchers demonstrated that ALP secretion into the serum was the direct result of the anchor deficiency.⁵ The same mechanism was subsequently confirmed for PIGO mutations, where affected children had ALP levels two to four times the upper limit of normal. One child’s ALP measured 1,872 U/l against a reference range of 200 to 700 U/l.⁶

Persistently elevated ALP in a child with seizures and intellectual disability should raise suspicion for an IGD, particularly subtypes previously grouped under the name hyperphosphatasia with mental retardation syndrome, or Mabry syndrome. That said, not every IGD subtype raises ALP. As noted earlier, PIGT mutations are more often associated with low ALP, making this biomarker useful but not universal across the family of disorders.

Flow Cytometry and Surface Marker Testing

Because GPI anchors tether specific proteins to the cell surface, measuring those proteins with flow cytometry offers a practical way to detect anchor deficiency. When GPI production is impaired, the surface expression of GPI-anchored markers drops. Different laboratories look at different markers, but CD55, CD59, and CD16 are among the most commonly tested.

In one study of siblings with PIGY mutations, skin cells showed a roughly 20 to 50 percent reduction in surface expression of CD55 and CD59 compared with control cells, confirming that the mutation disrupted GPI anchoring.⁷ In a separate case involving PIGW mutations, flow cytometry on white blood cells revealed a marked drop in CD16 on granulocytes, which led directly to the IGD diagnosis.⁸

Flow cytometry has the advantage of being relatively quick and widely available compared with specialized genetic sequencing. A clinician who suspects IGD can order this test as an early screen before committing to whole-exome or whole-genome sequencing, though genetic testing is ultimately needed to pinpoint the exact gene and variant. The PIGW case also flagged recurrent infections and complement abnormalities, a reminder that reduced surface expression of complement-regulatory proteins like CD55 and CD59 has real immunological consequences beyond being a convenient lab marker.

Treatment Options Remain Limited

There is no cure for IGD, and management is largely supportive. Seizure control is usually the most urgent clinical priority, and it is often frustrating. Standard antiepileptic medications frequently fail to bring seizures under adequate control, which prompted interest in vitamin B6 as an alternative. The rationale is that some GPI-anchored proteins are involved in vitamin B6 metabolism, and supplementing pyridoxine or its active form, pyridoxal-5′-phosphate (P5P), might partially compensate for their reduced surface expression.

A cohort study evaluating this approach found mixed results. Among seven participants treated with pyridoxine or P5P, two experienced more than a 50 percent reduction in seizure frequency, and another three had a smaller but still measurable reduction. None achieved seizure freedom, and EEG patterns did not change meaningfully in most cases.⁹ The takeaway is that B6 supplementation helps some children partially, but it is not a reliable solution on its own.

A more dramatic example of targeted therapy emerged from a child with PIGM mutations. PIGM is unusual among PIG genes because the disease-causing mutations in that case affected the gene’s promoter region rather than the protein itself. The child’s cells could still make the PIGM protein, but at levels too low to support adequate GPI production. Researchers found that butyrate, a histone deacetylase inhibitor, could crank up transcription of PIGM by loosening the chromatin around its promoter. When the drug was given to the child, who had intractable seizures, the seizures stopped completely.¹⁰ This remains one of the few examples of truly targeted therapy in any IGD subtype, though it only works for mutations that suppress gene expression rather than break the protein’s structure.

Why the Pathway Is So Conserved

The fact that yeast, which diverged from humans over a billion years ago, uses essentially the same GPI anchor pathway highlights how fundamental this system is to eukaryotic life. The yeast gene GPI19 is a functional equivalent of human PIG-P, and deleting it in yeast is lethal.¹¹ This extreme conservation means two things for researchers. First, yeast can serve as a practical model system for testing how specific mutations disrupt GPI assembly. If a variant of uncertain significance is found in a human patient, introducing the equivalent change in yeast and measuring its effect on GPI production can help determine whether the variant is truly pathogenic.

Second, the evolutionary persistence of GPI anchoring suggests that no alternative tethering mechanism has ever successfully replaced it for the class of proteins that use it. Hundreds of cell-surface proteins rely on GPI anchors in humans, and the pathway appears in protozoa, fungi, plants, and animals alike. Parasites like Trypanosoma, the organism behind sleeping sickness, coat themselves in GPI-anchored proteins to evade the host immune system, making the pathway a drug target in infectious disease research as well as a cause of rare pediatric disease.

Overlap With Paroxysmal Nocturnal Hemoglobinuria

People reading about GPI deficiency may encounter the name paroxysmal nocturnal hemoglobinuria, or PNH, which is a more common and very different condition that also involves GPI anchor loss. In PNH, a somatic mutation in the PIGA gene arises in a single blood stem cell after birth, causing a clone of blood cells that lacks GPI-anchored surface proteins. Because those cells cannot display the complement regulators CD55 and CD59, they are destroyed by the body’s own complement system, leading to episodes of red blood cell destruction, blood clots, and dark urine.

The crucial distinction is that PNH is acquired, not inherited. It affects only blood cells descended from the mutant clone, and the rest of the body is normal. Inherited GPI deficiency disorders, by contrast, affect every cell from conception. This is why IGD produces neurological and developmental symptoms that PNH does not. The two conditions share the same biochemical pathway but sit at opposite ends of the clinical spectrum, and confusing them can lead families down the wrong informational rabbit hole.

Getting a Diagnosis

Reaching a diagnosis of IGD can take years, partly because the conditions are rare and partly because the features overlap with many other genetic syndromes that cause seizures and intellectual disability. Elevated ALP on routine blood work, when present, is a useful red flag that can accelerate the process. Flow cytometry of blood cells can then support the diagnosis if GPI-anchored markers are reduced. Confirmation comes from genetic sequencing, typically whole-exome sequencing, which surveys all protein-coding genes at once rather than testing one gene at a time.

For families, the practical value of a genetic diagnosis goes beyond naming the condition. It determines recurrence risk for future pregnancies, since most IGD subtypes follow autosomal recessive inheritance, meaning both parents are unaffected carriers. It also opens the door to connecting with other families who share the same specific gene variant, which matters both for emotional support and for participation in natural history studies that could lay groundwork for future treatments. The PIGM-butyrate case illustrates that knowing the exact molecular defect can occasionally lead to a targeted intervention, though that remains the exception rather than the rule for now.

Immune Consequences Beyond the Brain

Because several immune-relevant proteins depend on GPI anchors, IGD does not stop at the nervous system. The complement regulators CD55 and CD59 are among the most clinically important GPI-anchored proteins, and their reduced expression leaves cells vulnerable to damage by the complement cascade. In the PIGW case described earlier, the affected individual had not only low CD16 on immune cells but also recurrent infections and measurable complement abnormalities.¹² This suggests that immune surveillance and infection susceptibility deserve more attention in the clinical management of IGD, especially in subtypes where complement defense is likely compromised.

CD16, the marker that flagged the PIGW diagnosis, is a receptor on natural killer cells and neutrophils that helps these immune cells recognize and destroy antibody-coated targets. Reduced CD16 could plausibly impair the body’s ability to clear certain infections, though detailed immunological studies in IGD patients remain sparse. As more cases are identified through broader genetic testing, the immune dimension of these disorders will likely come into sharper focus, potentially influencing decisions about vaccinations, prophylactic antibiotics, and infection monitoring in affected children.